| Aug 2 |
Takeda Pharmaceutical Company Limited (TAK) Q1 2025 Earnings Call Transcript
|
| Aug 1 |
Takeda’s revenue climbs by 14.1% in Q1 FY2024
|
| Jul 31 |
Takeda Pharmaceutical Non-GAAP EPS of ¥176.00, revenue of ¥1208B; reaffirms FY24 outlook
|
| Jul 31 |
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
|
| Jul 30 |
Takeda Pharmaceutical Q1 Earnings Preview
|
| Jul 19 |
Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline
|
| Jul 15 |
Shire Leasing accredited to deliver Growth Guarantee Scheme
|
| Jul 8 |
Polpharma looks to challenge Takeda’s Entyvio in IBD
|
| Jun 26 |
Takeda Announces New Assignments of Directors
|
| Jun 25 |
Wave jumps on trial data for Huntington’s disease therapy
|
